Dinutuximab Combination Therapy for High-Risk Neuroblastoma
Adding dinutuximab to induction chemotherapy, surgery, radiation, stem cell transplantation, and immunotherapy improves outcomes in children with newly diagnosed high‑risk neuroblastoma.
Evidence level: Irányelv / elfogadott gyakorlat. Magas szintű klinikai elfogadottság.
Related signals
- Targeted immunotherapies for anaplastic lymphoma kinase-positive pediatric tumors: current advances and future perspectives
- Updates in Diagnosis, Management, and Treatment of Neuroblastoma
- Coexpression of MYCN and ALK Induces Neuroblastoma-Like Tumors From Human iPS Cell-Derived Cranial Neural Crest Cells.
- Emerging clinical and research approaches in targeted therapies for high-risk neuroblastoma
- Frequency and Clinical Significance of Clonal and Subclonal Driver Mutations in High‑Risk Neuroblastoma at Diagnosis: A Children's Oncology Group Study